S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Xencor (XNCR) Stock Price, News & Analysis

$22.42
+0.89 (+4.13%)
(As of 03/27/2024 ET)
Today's Range
$21.34
$22.44
50-Day Range
$18.65
$26.52
52-Week Range
$16.49
$30.21
Volume
494,569 shs
Average Volume
914,528 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.71

Xencor MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
59.3% Upside
$35.71 Price Target
Short Interest
Bearish
9.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$3.09 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.24) to ($3.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

256th out of 939 stocks

Pharmaceutical Preparations Industry

113th out of 430 stocks

XNCR stock logo

About Xencor Stock (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

XNCR Stock Price History

XNCR Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
XNCR Apr 2024 30.000 call
XNCR May 2024 22.500 put
Xencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Xencor Inc XNCR
Xencor Full Year 2023 Earnings: Misses Expectations
Xencor Q4 2023 Earnings Preview
Xencor to Present at Upcoming Investor Conferences
Unveiling 4 Analyst Insights On Xencor
Xencor (XNCR) Gets a Buy from TD Cowen
Xencor: Q4 Earnings Snapshot
Xencor earnings preview: what Wall Street is expecting
6XNCR : Earnings Preview: Xencor
KPTI Aug 2024 1.000 call
KPTI May 2024 2.000 put
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XNCR
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.71
High Stock Price Target
$50.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+59.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-126,090,000.00
Pretax Margin
-71.55%

Debt

Sales & Book Value

Annual Sales
$168.34 million
Book Value
$10.99 per share

Miscellaneous

Free Float
58,082,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
0.77
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 54)
    Co-Founder, CEO, President & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 65)
    Senior VP & CFO
    Comp: $660.75k
  • Dr. John R. Desjarlais Ph.D. (Age 60)
    Executive VP of Research & Chief Scientific Officer
    Comp: $711.45k
  • Ms. Celia E. Eckert J.D. (Age 51)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $646.25k
  • Dr. Nancy Valente M.D. (Age 65)
    Executive VP & Chief Development Officer
    Comp: $28.16k
  • Mr. Charles Liles
    Associate Director and Head of Corporate Communications & Investor Relations
  • Ms. Jennifer Sandoz
    Vice President of Human Resources
  • Dr. Jeremy Grunstein Ph.D.
    Senior Vice President of Business Development
  • Mr. Kirk Rosemark RAC (Age 59)
    Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Eric P. Kowack
    Senior Vice President of Program Leadership & Alliance Management

XNCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price target for 2024?

8 Wall Street research analysts have issued 1 year target prices for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's stock price to reach $35.71 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2024?

Xencor's stock was trading at $21.23 at the start of the year. Since then, XNCR shares have increased by 5.6% and is now trading at $22.42.
View the best growth stocks for 2024 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.36 by $0.67. The biopharmaceutical company earned $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative trailing twelve-month return on equity of 18.67% and a negative net margin of 74.90%. The firm's quarterly revenue was up 106.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) EPS.

What ETFs hold Xencor's stock?
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.62%), Vanguard Group Inc. (11.12%), Vanguard Group Inc. (11.07%), Price T Rowe Associates Inc. MD (5.72%), Price T Rowe Associates Inc. MD (5.72%) and Armistice Capital LLC (2.46%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XNCR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners